efgartigimod

  1. ME/CFS Skeptic

    Medscape: FDA Approves New Myasthenia Gravis Drug

    The US Food and Drug Administration (FDA) has approved efgartigimod (Vyvgart, argenx), a first-in-class, targeted therapy for adults with generalized myasthenia gravis (gMG) who test positive for the antiacetylcholine receptor (AChR) antibody... Full text at...
Back
Top Bottom